1. Scrip
  2. >>Focus On Asia
  3. >>India

IndiPharm appoints new director of operations

 
• By Zoë Dann

The US CRO IndiPharm has appointed Nigel McBean vice-president and director of operations at its operational headquarters in Mumbai, India. Mr McBean was formerly director of multicentre research for PRACS Institute (now part of the Cetero Research Group) and has also worked at MedImmune and GlaxoSmithKline.

The US CRO IndiPharm has appointed Nigel McBean vice-president and director of operations at its operational headquarters in Mumbai, India. Mr McBean was formerly director of multicentre research for PRACS Institute (now part of the Cetero Research Group) and has also worked at MedImmune and GlaxoSmithKline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

India’s R&D Funding Push: Catalytic To De-Risking Early Innovation?

 
• By Anju Ghangurde

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.

GLP-1s: Lilly, Novo Gallop In India, Generic Firms Gear ‘To Finish The Race’

 
• By Anju Ghangurde

Leaders from Eli Lilly, Novo Nordisk, Biocon, Dr Reddy’s and Levim discuss the huge India market potential for GLP-1s. Executives from the Indian firms also outlined efforts to build supply chain stability and cost-efficiency for products like semaglutide.

Lupin’s €190m VISUfarma Deal Helps US De-Risking, Boosts Specialty Business

 
• By Vibha Ravi

Lupin’s €190m VISUfarma acquisition brings over 60 prescription and over the counter (OTC) products across ophthalmology to its specialty drug business while lowering the company’s risk to current vagaries in the US market from tariffs to MFN pricing

Blueprint To Deliver A Blockbuster Drug In India

 
• By Anju Ghangurde

Leaders from MSD, Immuneel Therapeutics and ICICI Lombard discuss the pathway and potential models to deliver a billion-dollar therapy in India.

More from Focus On Asia

Chinese Cell And Gene Therapy Developers Ride Funding Spree

 
• By Dexter Jie Yan

Suzhou-based Accuredit Therapeutics led the pack of recent China financings with a $75m series A. Other major funding rounds in the country backed by venture capital and private equity firms included Beijing GRIT Biotechnology's $53.5m series C.

US Confirms 15% Tariff On Japanese Drugs, But Confusion Lingers

 
• By Lisa Takagi

After tough negotiations which won the country a lower US levy on pharmaceuticals, there still appears to be some confusion within the Japanese government following President Trump's latest announcement on global pharma tariffs.

GLP-1s: Lilly, Novo Gallop In India, Generic Firms Gear ‘To Finish The Race’

 
• By Anju Ghangurde

Leaders from Eli Lilly, Novo Nordisk, Biocon, Dr Reddy’s and Levim discuss the huge India market potential for GLP-1s. Executives from the Indian firms also outlined efforts to build supply chain stability and cost-efficiency for products like semaglutide.